Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;13(1):8-19.
doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

Randall J Bateman  1 , Tammie L Benzinger  2 , Scott Berry  3 , David B Clifford  4 , Cynthia Duggan  4 , Anne M Fagan  4 , Kathleen Fanning  4 , Martin R Farlow  5 , Jason Hassenstab  4 , Eric M McDade  4 , Susan Mills  4 , Katrina Paumier  4 , Melanie Quintana  3 , Stephen P Salloway  6 , Anna Santacruz  4 , Lon S Schneider  7 , Guoqiao Wang  8 , Chengjie Xiong  8 ; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network
Affiliations

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

Randall J Bateman et al. Alzheimers Dement. 2017 Jan.

Abstract

Introduction: The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial.

Methods: In collaboration with ADAD families, philanthropic organizations, academic leaders, the DIAN-TU Pharma Consortium, the National Institutes of Health, and regulatory colleagues, the DIAN-TU developed innovative clinical study designs for the DIAN-TU NexGen prevention trial.

Results: Our expanded trial toolbox consists of a disease progression model for ADAD, primary end point DIAN-TU cognitive performance composite, biomarker development, self-administered cognitive assessments, adaptive dose adjustments, and blinded data collection through the last participant completion.

Conclusion: These steps represent elements to improve efficacy of the adaptive platform trial and a continued effort to optimize prevention and treatment trials in ADAD.

Keywords: Adaptive clinical trial; Alzheimer's disease; Alzheimer's prevention trial; Amyloid; Autosomal dominant Alzheimer's disease; Biomarkers; Cognitive composite; DIAN-TU; Disease progression model; Dose adjustment; Tau.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Existing and proposed structure of the DIAN-TU trial platform including the Next Generation Prevention Trial. Pink indicates enrollment of the first two arms, pink and green the biomarker phase, and green denotes graduation to a cognitive endpoint. In this article we describe design considerations for the two NexGen arms including proposed interim analyses based on biomarkers and performance on the DIAN-TU cognitive composite.
Figure 2
Figure 2
Current and possible future DIAN-TU and DIAN Observational study sites. The trial is active at 26 sites in 7 countries.
Figure 3
Figure 3
DIAN-TU Cognitive Composite performance by estimated year to symptom onset in Mutation Carriers (red, n=223) and Non-Carriers (black, n=142) from the DIAN Observational Study Data Freeze 9. The four components of the test include Logical Memory Delayed Recall, DIAN Word List Test (comparable to International Shopping List Test used in DIAN-TU), Digit Symbol Coding and MMSE.
Figure 4
Figure 4
Longitudinal and Cross-Sectional Cognitive Performance in Mutation Carriers. Disease progression modeling demonstrating the dramatic improvement in variance for cognitive decline (right panel) after accounting for subject level EYO and subject level baseline cognitive performance.
Figure 5
Figure 5
Proportional hypothetical treatment effects yield different absolute changes depending on EYO. The red line represents the natural (i.e. placebo) rate of cognitive decline across EYO. The colored lines illustrate different levels of slowing disease progression based on drug effect across EYO.
See this image and copyright information in PMC

References

    1. Brookmeyer R, Evans DA, Hebert L, Langa KM, Heeringa SG, Plassman BL, Kukull WA. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 2011;7(1):61–73. doi: 10.1016/j.jalz.2010.11.007. PubMed PMID: 21255744; PMCID: 3052294. - DOI - PMC - PubMed
    1. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's research & therapy. 2011;3(1):1. doi: 10.1186/alzrt59. Epub 2011/01/08. PubMed PMID: 21211070; PMCID: 3109410. - DOI - PMC - PubMed
    1. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, Network DIA. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253–60. doi: 10.1212/WNL.0000000000000596. PubMed PMID: 24928124; PMCID: PMC4117367. - DOI - PMC - PubMed
    1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Dominantly Inherited Alzheimer N. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795–804. doi: 10.1056/NEJMoa1202753. PubMed PMID: 22784036; PMCID: 3474597. - DOI - PMC - PubMed
    1. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–7. doi: 10.1038/22124. PubMed PMID: 10408445. - DOI - PubMed

Publication types

Substances